Apogee Therapeutics

Robust Pipeline of 50+ Therapies Reshaping Moderate to Severe Atopic Dermatitis Treatment Landscape

4 days ago

• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition. • Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments. • Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.

Apogee's Novel Atopic Dermatitis Drug APG777 Shows Promising Safety and Extended Half-Life in Phase 1 Trial

3 months ago

• APG777, Apogee Therapeutics' investigational antibody for atopic dermatitis, demonstrated favorable safety profile and extended half-life in Phase 1 healthy volunteer study. • The drug candidate showed potential for monthly or less frequent dosing regimen, offering a significant advantage over existing treatments in the atopic dermatitis space. • Initial pharmacokinetic data supports further clinical development, with Phase 2 trials planned to evaluate efficacy in atopic dermatitis patients.

Apogee Therapeutics to Present Phase 1 APG990 Trial Results for Inflammatory Disease Treatment

3 months ago

• Apogee Therapeutics will announce interim results from its Phase 1 healthy volunteer trial of APG990, advancing their portfolio of novel biologics for inflammatory and immunology conditions. • The company will discuss combination strategy plans for APG777 and APG990, targeting improved efficacy in conditions including atopic dermatitis, asthma, and eosinophilic esophagitis. • The presentation will take place on March 3, 2025, at 8:30 AM ET via webcast, highlighting Apogee's progress in developing advanced antibody therapeutics for underserved patient populations.

Apogee Therapeutics Advances APG777 for Atopic Dermatitis Treatment with Phase 2 Trial Progress

6 months ago

• Apogee Therapeutics has dosed the first patient in Part B of the Phase 2 APEX trial for APG777, targeting moderate-to-severe atopic dermatitis. • Enrollment in Part A of the APEX trial was completed ahead of schedule, exceeding the target with 123 patients enrolled, indicating strong interest. • APG777 is a novel, subcutaneous monoclonal antibody with an extended half-life, designed for less frequent dosing and improved clinical responses. • Topline data from Part A of the Phase 2 study is expected in mid-2025, with further trials planned for asthma and eosinophilic esophagitis.

Former Seagen CEO Leads Ottimo Pharma's Novel Cancer Immunotherapy Development

7 months ago

• David Epstein, former Seagen CEO, takes helm at Ottimo Pharma to develop jankistomig, a novel bi-functional antibody targeting both PD-1 and VEGFR2 for cancer treatment. • Ottimo Pharma emerges from stealth with Medicxi backing, planning to initiate clinical trials in 2025 for their innovative immunotherapy approach targeting solid tumors. • The company's technology aims to improve upon existing cancer immunotherapies by targeting dual pathways, following recent successful results of similar approaches in lung cancer trials.